Melioidosis, caused by Burkholderia pseudomallei, is a life-threatening infectious disease found in contaminated and hazardous water and soil. This disease manifests in various forms, from asymptomatic conditions to severe respiratory distress and septic shock. Immunocompromised individuals, particularly those with diabetes, are at a higher risk of severe melioidosis. This article explores the epidemiology, pathophysiology, clinical presentation, diagnosis, treatment, and prevention of melioidosis in immunocompromised patients.

What is Meliodosis?

Melioidosis, also known as Whitmore's disease, is an infectious disease caused by Burkholderia pseudomallei, a Gram-negative bacillus endemic to Southeast Asia and Northern Australia. The bacterium is found in contaminated water and soil and can infect humans through inhalation, inoculation, and ingestion. Although person-to-person transmission is rare, melioidosis can cause a spectrum of conditions from asymptomatic infections to severe disease, including pneumonia, septicemia, and organ abscesses. Immunocompromised patients, especially those with diabetes, are particularly susceptible to severe forms of melioidosis.

Epidemiology

Melioidosis is predominantly found in tropical regions, with the highest incidence in Southeast Asia and Northern Australia. In these endemic regions, melioidosis is a significant cause of community-acquired pneumonia and septicemia, with mortality rates reaching up to 44%.¹ The disease's incidence is increasing in other parts of the world, including India and China, possibly due to better diagnostic facilities and increased awareness. Immunocompromised individuals are those whose immune systems are weakened or not functioning properly, making them more susceptible to infections. This compromised state can be due to a variety of conditions or treatments.

Diabetes: Patients with diabetes have an impaired immune response due to high blood sugar levels, which can interfere with the ability of white blood cells to respond to infections effectively. This leads to a higher susceptibility to infections, including melioidosis.

Chronic Kidney Disease (CKD): CKD patients often have a weakened immune system due to the disease itself and the treatments involved, such as dialysis. This makes them more vulnerable to infections as their bodies cannot mount an effective immune response.

Immunosuppressive Therapy: Patients undergoing immunosuppressive therapy, such as those with organ transplants or autoimmune diseases, are at significant risk because these treatments intentionally weaken the immune system to prevent organ rejection or to control autoimmune activity. However, this suppression of the immune response also reduces the body’s ability to fight off infections, increasing the risk of severe diseases like melioidosis.

Pathophysiology

B. pseudomallei enters the body through skin abrasions, inhalation, or ingestion. Once inside the host, the bacterium can evade the immune system and disseminate to various organs, leading to localised or systemic infections. The pathogen’s ability to form biofilms and its resistance to many antibiotics contribute to the chronic and relapsing nature of melioidosis. In immunocompromised patients, the body's weakened immune defences allow the bacteria to multiply and spread more easily, leading to severe infections. The pathogen's intracellular lifestyle, involving survival within macrophages, further complicates eradication efforts.

Clinical presentation

The clinical manifestations of melioidosis vary widely, ranging from asymptomatic infections to life-threatening septicemia. In immunocompromised patients, the disease often presents more aggressively. Common symptoms include high fever, chills, and rigors, which can progress to severe respiratory distress, septic shock, and multiple organ abscesses. Patients often present with poorly controlled glycemia, significant weight loss, and joint involvement, such as septic arthritis. Chronic melioidosis can mimic other conditions like tuberculosis, making diagnosis challenging. Additionally, in immunocompromised patients, atypical presentations are common, including protracted fever of unknown origin, chronic lung infections, and abscess formation in unusual sites like the prostate or parotid gland.

How is it diagnosed? 

The diagnosis of melioidosis involves clinical evaluation, microbiological testing, and imaging studies. Blood cultures are essential for detecting B. pseudomallei, though the bacterium can also be isolated from other body fluids or tissues. Imaging techniques, such as ultrasound, CT scans, and X-rays, help identify abscesses and other localised infections. Serological tests and molecular methods like PCR can also aid in diagnosis. Due to the diverse presentations and similarity to other diseases, a high index of suspicion is necessary, particularly in immunocompromised patients from endemic areas. Early and accurate diagnosis is critical as delayed treatment can lead to increased morbidity and mortality.

Treatment

The treatment of melioidosis involves prolonged antibiotic therapy due to the pathogen's resistance and ability to cause chronic infection. The initial intensive phase typically includes intravenous antibiotics such as meropenem or ceftazidime for at least 10-14 days, followed by an eradication phase with oral antibiotics like cotrimoxazole or doxycycline for 3-6 months. In severe cases, combination therapy may be necessary. Surgical intervention may be required for drainage of abscesses. Early diagnosis and prompt treatment are crucial for reducing mortality, especially in immunocompromised patients.

Antibiotic therapy

• Intensive Phase: The intensive phase involves intravenous antibiotics such as ceftazidime, meropenem, or imipenem. The choice of antibiotic depends on the severity of the disease and the patient's overall condition. This phase usually lasts for at least 10-14 days but may be extended in cases of severe infection or complications.
• Eradication Phase: The eradication phase aims to prevent relapse and typically involves oral antibiotics such as cotrimoxazole or doxycycline for 3-6 months. For patients intolerant to cotrimoxazole, alternatives like amoxicillin-clavulanate may be considered.

Supportive care and surgical intervention

In addition to antibiotic therapy, supportive care is crucial, especially in severe cases involving septic shock or multi-organ failure. This includes fluid resuscitation, vasopressors, and organ support as needed. Surgical intervention may be required to drain abscesses or debride infected tissues, particularly in patients with large or poorly accessible abscesses.

Prevention

Preventing melioidosis involves minimising exposure to contaminated water and soil, particularly for high-risk individuals such as those with diabetes. Protective measures include wearing appropriate footwear and gloves when working in soil or water, avoiding direct contact with contaminated sources, and ensuring proper wound care. In endemic areas, raising awareness about the disease among healthcare providers and the public is essential for early recognition and treatment. Vaccination research is ongoing, but no effective vaccine is currently available. Public health strategies focusing on education, early detection, and prompt treatment can significantly reduce the burden of melioidosis in vulnerable populations.

Prevention Strategies: To reduce the risk of infections, immunocompromised patients should adhere to several preventive measures:

• Hygiene: Maintaining strict personal hygiene, including regular hand washing with soap and water, is crucial. Avoiding contact with soil and standing water, which can harbour infectious agents, is particularly important in endemic areas
• Vaccinations: Many immunocompromised patients can benefit from inactivated vaccines to prevent common infections. It is essential to follow the vaccination schedule recommended by healthcare providers
• Diet and Nutrition: A balanced diet rich in vitamins and minerals supports overall health and immune function. Patients should avoid raw or undercooked foods that may carry harmful bacteria.
• Antimicrobial Prophylaxis: In certain cases, healthcare providers may prescribe prophylactic antibiotics or antifungal medications to prevent specific infections
• Regular Medical Check-ups: Frequent monitoring and early detection of potential infections are vital. Immunocompromised patients should have regular consultations with their healthcare providers to manage their underlying conditions and adjust treatments as needed
• Environmental Precautions: Avoiding exposure to environments known to harbour infectious agents, such as areas with high levels of soil disturbance, is essential. Patients should wear protective clothing and equipment when exposure to such environments is unavoidable
• Education and Awareness: Patients and their caregivers should be educated about the signs and symptoms of infections, so they can seek prompt medical attention if necessary

Summary

Melioidosis is a serious infectious disease with a high mortality rate, particularly in immunocompromised patients. The disease's diverse clinical presentations and similarity to other infections pose significant diagnostic challenges. Early diagnosis, appropriate antibiotic therapy, and preventive measures are vital in managing melioidosis and reducing its impact on vulnerable populations. Further research and public health initiatives are needed to improve the understanding, diagnosis, and treatment of this potentially fatal disease.